SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems

SOPHiA GENETICS (NASDAQ: SOPH) announced the addition of two major U.S. integrated health systems to its network, expanding use of the AI-native, cloud-based SOPHiA DDM™ across West Coast and Midwest laboratories.

Rhea-AI Summary

SOPHiA GENETICS (NASDAQ: SOPH) announced the addition of two major U.S. integrated health systems to its network, expanding use of the AI-native, cloud-based SOPHiA DDM™ across West Coast and Midwest laboratories.

The institutions will initially launch genomic testing for up to 60,000 patients annually, use Enhanced Exome for analysis of over 20,000 genes, and together serve a combined population of nearly one million cancer and rare disorder patients.

Positive

• Capacity to support genomic testing for up to 60,000 patients annually
• Onboards two major U.S. health systems, including a top-10 lab
• Enhanced Exome analytics covering over 20,000 genes
• Combined reach covers nearly one million cancer and rare-disorder patients annually

Negative

• None.

Argus Feb 10 session

-1.44% close to close Open Argus

Details

News Market Reaction – SOPH

On Feb 10, the day this news came out, SOPH closed 1.44% below the previous close.

Data tracked by StockTitan Argus for the Feb 10 session.

Key Figures

Annual genomic testing volume: up to 60,000 patients annually Genes analyzed: over 20,000 genes Patient population served: nearly one million patients annually

Annual genomic testing volume

up to 60,000 patients annually

Initial genomic testing rollout across West Coast and Midwest health systems

Genes analyzed

over 20,000 genes

Enhanced Exome application for full-exome analysis on SOPHiA DDM

Patient population served

nearly one million patients annually

Combined cancer and rare disorder patients at the two health systems

Historical Context

5 past events · Latest: Jan 15

5 events

1. Jan 15

   Innovation awards

   24h Move

   +0.2%

   Multiple BIG Innovation Awards for advanced coatings technologies and sustainability benefits.

2. Jan 12

   Prelim earnings & guidance

   24h Move

   -2.6%

   Preliminary 2025 results, 2026 revenue and EBITDA guidance, and planned CEO transition.

3. Jan 07

   AI oncology partnership

   24h Move

   +4.2%

   Strategic collaboration with MD Anderson to co-develop AI-driven oncology NGS tests.

4. Nov 11

   Platform integration

   24h Move

   +6.2%

   Integration of MSK-IMPACT and MSK-ACCESS assays on DNBSEQ-T1+ using SOPHiA DDM.

5. Nov 11

   AI co-marketing deal

   24h Move

   +6.2%

   Co-marketing of MSK assays with SOPHiA DDM on DNBSEQ-T1+ targeting precision oncology labs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

genomic, exome, bioinformatics

3 terms

genomic medical

"analyze complex genomic data at scale"

Relating to an organism’s genome — the complete set of DNA instructions that determine traits and biological functions — and to the study or use of that information. For investors, genomic technologies and data underpin diagnostics, targeted medicines, and personalized treatments, shaping potential market size, product timelines, and regulatory risk; think of it as reading an instruction manual to design precise medical products, which can speed innovation but also bring scientific and approval uncertainty.

exome medical

"supports comprehensive full-exome analysis for over 20,000 genes"

The exome is the portion of an organism’s genetic code that carries the instructions for making proteins — like the highlighted pages in a huge instruction manual that contain the actual recipes. It matters to investors because many genetic tests, drug targets and diagnostics focus on these protein-making instructions; finding disease-linked changes there can speed development of treatments, reduce research costs, and drive commercial value.

bioinformatics medical

"Combining advanced bioinformatics, the collective knowledge of a global community"

The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.

The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S. and a top 10 U.S. health system laboratory. Together, these institutions will leverage the AI-native, cloud-based SOPHiA DDM^™ to analyze complex genomic data at scale.

By adopting SOPHiA DDM^™, the two institutions will initially launch genomic testing for up to 60,000 patients annually across the West Coast and Midwest, enabling faster diagnosis and more personalized care for individuals living with hereditary cancers and rare diseases.

Both health systems will utilize SOPHiA DDM™ for Enhanced Exome, an AI-driven analytics application that supports comprehensive full-exome analysis for over 20,000 genes while enabling the ability to dive deeper into clinically relevant regions. With these capabilities directly embedded into their laboratory workflows, the institutions aim to expedite testing turnaround times, streamline operational costs, and expand internal research and innovation initiatives.

John Carey, Managing Director, North America, SOPHiA GENETICS, said: "Partnering with two of the largest health systems in the U.S. underscores the growing need for AI-powered genomic solutions capable of addressing increasingly complex use cases that can scale without adding operational burden. Combining advanced bioinformatics, the collective knowledge of a global community, and streamlined workflows, our AI enables healthcare institutions to unlock deeper insights."

Going forward, this collaboration positions both organizations with a scalable foundation to support future expansion of AI-driven precision medicine. Each year, these organizations serve a combined population of nearly one million cancer and rare disorder patients nationwide.

SOPHiA GENETICS continues to strengthen its presence in the United States while supporting leading healthcare institutions across some of the most complex areas of precision medicine. The expansion in the region reinforces the company's mission to democratize data-driven medicine by equipping researchers and clinicians with AI-powered solutions that accelerate healthcare innovation and research.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.com or connect on LinkedIn. 

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-major-expansion-in-the-united-states-with-the-signing-of-two-major-integrated-health-systems-302683856.html

SOURCE SOPHiA GENETICS

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does SOPH announced on February 10, 2026 about U.S. expansion?

SOPH added two large U.S. health systems to its network to scale genomic testing. According to the company, the partnership deploys SOPHiA DDM™ across West Coast and Midwest sites to accelerate diagnosis and expand precision-medicine workflows.

How many patients will SOPH support annually with the new U.S. partnerships (SOPH)?

The partnerships will initially support genomic testing for up to 60,000 patients annually. According to the company, that capacity targets hereditary cancer and rare-disease testing across the participating West Coast and Midwest laboratories.

What is Enhanced Exome and how will SOPH use it with new partners (SOPH)?

Enhanced Exome is an AI-driven full-exome analytics application covering over 20,000 genes. According to the company, it enables deeper analysis of clinically relevant regions integrated directly into laboratory workflows for faster, richer genomic insights.

Which U.S. regions and types of institutions will SOPH serve through this expansion (SOPH)?

The expansion covers laboratories on the West Coast and in the Midwest and includes a nonprofit multi-region integrated system and a top-10 health system lab. According to the company, both institutions will adopt SOPHiA DDM™ for clinical and research use.

What investor-relevant scale does the SOPH expansion claim to achieve?

The company cites a combined served population of nearly one million cancer and rare-disorder patients annually. According to the company, this positions the partnerships as a scalable foundation for broader AI-driven precision medicine growth.